Is Edwards Lifesciences Corporation (EW) A Good Stock To Buy Now?

Core Thesis - Edwards Lifesciences Corporation (EW) is viewed positively as a stock investment, with a current trading price of $83.92 and trailing and forward P/E ratios of 46.17 and 28.49 respectively [1]. Company Overview - Edwards Lifesciences specializes in products and technologies for advanced cardiovascular diseases, having transitioned into a pure-play leader in structural heart disease after divesting its Critical Care business for $4.2 billion [2]. Financial Performance - The divestiture removed approximately 20% of the company's 2023 EBITDA base, but this has been offset by the rapid growth of the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment, which is expanding over 50% year-over-year [3]. - The core Transcatheter Aortic Valve Replacement (TAVR) franchise generates over $4.5 billion in annual revenue with growth exceeding 12%, providing a stable foundation for the company [4]. Valuation and Investment Potential - Following a recent pullback, Edwards Lifesciences is trading at approximately $78, supported by strong fundamentals such as 78% gross margins and a solid balance sheet with $3.8 billion in cash [5]. - The company's valuation of around 21.3x EV/NTM EBITDA is below its historical average of 26x, indicating potential for multiple expansion alongside expected EBITDA growth of 10-11% CAGR [5]. Growth Outlook - With ongoing share repurchases and disciplined capital allocation, Edwards Lifesciences is positioned for sustained double-digit earnings growth, driven by demographic trends and innovation in transcatheter therapies [6]. - A favorable scenario combining earnings expansion and multiple re-rating could lead to compelling double-digit annualized returns from current levels [6].